MCAM and neoplasm: Of importance, the combination of bevacizumab and mucizumab antibodies exhibits a potential therapeutic benefit by significantly decreasing EMT and CSC in CD146 + bevacizumab-resistant glioblastoma cells in vitro, as well as potently decreasing tumor growth in a pre-clinical model of glioblastoma orthotopically injected in nude mice.